Biogen (NASDAQ: BIIB) reported Q4 EPS of $1.99, $0.38 better than the analyst estimate of $1.61. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.21 billion.

GUIDANCE:

Biogen sees FY2026 EPS of $15.25-$16.25, versus the consensus of $14.92.

For earnings history and earnings-related data on Biogen (BIIB) click here.